Intesa invests 360 million euros to manage its entire health insurance business

Published Date: 08 Mar 2023

Italy's biggest conglomerate, Intesa Sanpaolo, has paid 360 million euros ($382 million) in cash to acquire a 26.2% stake in health insurer Intesa Sanpaolo RBM Salute, which it does not own. that it will be used.

Read Full News

Latest News

The Golden Handcuffs of Private Equity

Private equity firms are increasingly buying up smaller medical practices. Sometimes for the better, and sometimes not.

New Book Spotlights Medicine’s Emotional Side

A new anthology, Where It Hurts: Dispatches from the Emotional Frontlines of Medicine, explores how doctors process the day-to-day challenges of their careers.

Novel imaging approach may improve treatment for spinal cord injuries

Northwestern Medicine investigators have developed a new imaging approach to more accurately assess blood flow in the spinal cord, a method that could be used to better inform treatment for neurological diseases and injuries, ...

Tirzepatide may only temporarily suppress brain 'food noise' activity

A rare glimpse into the brain activity of a patient with obesity and loss of control eating on tirzepatide, marketed as Mounjaro and Zepbound, revealed that the medication suppresses signaling in the brain's "reward center" ...

Supercomputer simulation is changing how we study the brain

Harnessing the muscle of one of the world's fastest supercomputers, researchers have built one of the largest and most detailed biophysically realistic brain simulations of an animal ever.

AI tool creates digital twins of patients to predict their future health

A new artificial intelligence tool that can create virtual representations of patients and predict individual health trajectories has been hailed a potential gamechanger for the clinical trial sector.

Todays Updates

Biomarker Flags 10-Fold Recurrence Risk in Testicular Cancer

MiR-371 isn’t ready for the clinic yet, but it is ready for interventional trials to see if it can refine adjuvant chemotherapy decisions in stage I testicular cancer.

FDA Approves New Drug Combo for RR Multiple Myeloma

Teclistamab plus daratumumab and hyaluronidase-fihj is approved for relapsed or refractory MM after one prior line of therapy, including a proteasome inhibitor and immunomodulatory agent.

Todays Updates

Biomarker Flags 10-Fold Recurrence Risk in Testicular Cancer

MiR-371 isn’t ready for the clinic yet, but it is ready for interventional trials to see if it can refine adjuvant chemotherapy decisions in stage I testicular cancer.

FDA Approves New Drug Combo for RR Multiple Myeloma

Teclistamab plus daratumumab and hyaluronidase-fihj is approved for relapsed or refractory MM after one prior line of therapy, including a proteasome inhibitor and immunomodulatory agent.

Latest News

Private equity firms are increasingly buying up smaller medical practices. Sometimes for the better, and sometimes not.

A new anthology, Where It Hurts: Dispatches from the Emotional Frontlines of Medicine, explores how doctors process the day-to-day challenges of their careers.

Northwestern Medicine investigators have developed a new imaging approach to more accurately assess blood flow in the spinal cord, a method that could be used to better inform treatment for neurological diseases and injuries, ...

A rare glimpse into the brain activity of a patient with obesity and loss of control eating on tirzepatide, marketed as Mounjaro and Zepbound, revealed that the medication suppresses signaling in the brain's "reward center" ...

Harnessing the muscle of one of the world's fastest supercomputers, researchers have built one of the largest and most detailed biophysically realistic brain simulations of an animal ever.

A new artificial intelligence tool that can create virtual representations of patients and predict individual health trajectories has been hailed a potential gamechanger for the clinical trial sector.

News All Time

One of the world's oldest blood pressure drugs may also halt aggressive brain tumor growth

A Penn-led team has revealed how hydralazine, one of the world's oldest blood pressure drugs and a mainstay treatment for preeclampsia, works at the molecular level. In doing so, they made a surprising discovery—it can ...

From body fat to bone, experiment offers hope for 'gentle' repair of fractures

Japanese researchers are testing a surprising, minimally invasive way to repair spine fractures.

Software optimizes brain simulations, enabling them to complete complex cognitive tasks

A new software enables brain simulations which both imitate the processes in the brain in detail and can solve challenging cognitive tasks. The program was developed by a research team at the Cluster of Excellence "Machine ...

At some doctors' offices, AI is listening in the exam room

Bracken Babula starts patient visits these days by closing the exam room door and asking if they mind him recording their conversation. He hits a button on his mobile phone, checks that it is recording, and sits back in his ...

When life imitates art: Google searches for anxiety drug spike during run of The White Lotus TV show

In season three of the hit television series "The White Lotus," the character Victoria Ratliff takes the prescription anti-anxiety medication lorazepam to help with her social anxiety and inability to sleep. Her casual usage ...

GLP-1 and health: Beyond weight loss in the Ozempic era

This week, the White House announced a deal with Eli Lilly and Novo Nordisk to lower the cost of their GLP-1 weight loss drugs, Wegovy and Zepbound. The move could significantly expand access to these treatments for people ...

Digital access improves convenience, but cannot fully replace physical services

A research team from the Urban and Transportation Systems Laboratory, Department of Architecture and Civil Engineering, Toyohashi University of Technology, has developed an innovative evaluation framework that quantitatively ...

Computational deep dive reveals hidden cancer drug targets and repurposing opportunities

One person's side effect could be another person's treatment if we expand our perspective on small molecule drug targets, according to a new study published November 5, 2025, in npj Precision Oncology.

How the brain learns and applies rules: Sequential neuronal dynamics in the prefrontal cortex

Understanding how the brain learns and applies rules is the key to unraveling the neural basis of flexible behavior. A new study from the University of Toyama, Japan, reveals that our ability to follow procedural rules is ...

Deep learning system could transform skin cancer detection with near-perfect accuracy

Melanoma remains one of the hardest skin cancers to diagnose because it often mimics harmless moles or lesions. While most artificial intelligence (AI) tools rely on dermoscopic images alone, they often overlook crucial patient ...

Kidney organoids uncover Hippo signaling pathway as a therapeutic target for nephronophthisis

Using human-induced pluripotent stem cell-derived kidney organoids, researchers from Science Tokyo uncovered how abnormal Hippo signaling drives fibrosis in nephronophthisis, a genetic kidney disorder caused by NPHP1 deficiency.

Speeding the detection of three serious regional fungal infections

Certain serious fungal infections occur in regions of the United States with specific environments and are often tied to soil exposure. These infections can affect both healthy and immunocompromised people, but proper diagnosis ...

Wireless incubator enables remote monitoring of premature infants from 30 meters away

A wireless, portable incubator that could transform care for premature infants is reported in the International Journal of Medical Engineering and Informatics. It offers remote monitoring and automated environmental control ...

Molecular test could allow for more accurate Lyme disease diagnosis

Researchers at Dartmouth Hitchcock Medical Center have developed a way to diagnose Lyme disease earlier and more accurately than traditional testing methods.

Family history key to predicting antidepressant response

A new study from Queen Mary University of London shows that a family's experience with certain medicines could help doctors predict how future generations will respond to the same drugs.

FDA approves Darzalex Faspro for high-risk smoldering multiple myeloma

The U.S. Food and Drug Administration has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) as a single-agent treatment for adult patients with high-risk smoldering multiple myeloma (HR-SMM).

Recommended News For You

Pancreatic Cancer: A Novel CD40 Agonist-Chemo Combo Shows Promise.

New tumor therapy approach reduces costs and side effects while increasing accessibility

Achieves a High Disease Control Rate in Head and Neck BCC with Vismodegib-RT Regimen.

Patients with metastatic breast cancer can predict their response to HER2-targeted therapy using whole-body PET/CT.

Avoiding Neuropathy From Chemo; Predictive Value of Screening EKGs

Frontline EGFR/VEGF Inhibition Slows Advanced EGFR-Positive Lung Cancer

For cancer patients who are not responding to chemotherapy, new genes and natural toxins offer hope.

Recommended Articles For You

Understanding Macrocytosis: Causes, Symptoms, and Treatment Options  

Unmasking the Subtle Symptoms of Colon Cancer 

Neoadjuvant Abraxane Chemotherapy Combined with Neutrophil Cytopharmaceuticals and Radiotherapy 

Revolutionizing Cancer Treatment: How Adoptive Cell Therapy is Overcoming Tumor Immune Evasion 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Including Isatuximab with a Standard Backbone Enhances Multiple Myeloma Results.

2.

Charting the Course: From Young Adult Leukemia Patient to Oncologist.

3.

Screening for prostate cancer: is it time to give up digital rectal examination?

4.

Too Many Kids With Sickle Cell Disease Aren't Getting Appropriate Preventive Care

5.

Charles III, King of Kings, is Cancerous.

1.

The Growing Crisis of Aplastic Anemia: A Call for Action

2.

The Silent Killer: Uncovering the Causes and Treatments of Hemorrhagic Gastritis

3.

Hemophilia Beyond Boundaries: Unconventional Therapies in Bleeding Disorder Care

4.

Unlocking the Potential of Immune Checkpoint Inhibitors: A Pioneering Case Series on the Role of Immunotherapy in Microsatellite-Instability-High Colorectal Cancer

5.

Understanding Adenomyosis: The Role of Ultrasound in Diagnosis Introduction

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion

2.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation

3.

Optimizing Treatment Options in Advanced Urothelial Carcinoma

4.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part V

5.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot